CLRT Clarient, Inc. featured news, full reports, and detailed charts
Clarient, Inc. (CLRT) Wrap Up:
Clarient, Inc., a Delaware corporation ("Clarient", the "Company", "we", "us" or "our"), was founded and organized in 1993 and is headquartered in Aliso Viejo, California. Our vision is to improve the lives of those affected by cancer by bringing clarity to a complex disease. Our mission is to be the leader in cancer diagnostics by dedicating ourselves to collaborative relationships with the health care community as we translate cancer discovery and information into better patient care. With the completion of the human genome project in the late 1990s, medical science has entered a new era of diagnostics that will move us closer than ever before to understanding the molecular causes for complex diseases, particularly cancer. As a result, the landscape of cancer management is undergoing significant change. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f04%2f01%2f0001047469-08-003889.html#FIS_BUSINESS"Clarient, Inc. (CLRT:NASDAQ)
Snapshot of Clarient, Inc. (CLRT)
|
OPEN
$2.51
|
PREVIOUS CLOSE
$2.53
|
|
|
DAY HIGH
$2.63
|
DAY LOW
$2.45
|
|
|
52 WEEK HIGH
09/28/09 - $4.43
|
52 WEEK LOW
11/21/08 - $0.82
|
|
|
MARKET CAP
193.7M
|
AVERAGE VOLUME 3 mo
558.7K
|
|
|
DILUTED EPS TTM
$-0.15
|
SHARES OUTSTANDING
78.4M
|
|
|
CLRT Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
CLRT Top Compensated Officers
Executives, Board Directors
Key developments for Clarient, Inc. (CLRT)
Clarient Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009. Results included a 13% increase in net revenues for the third quarter of 2009 as compared to the third quarter of 2008. Third quarter net revenue was $21.4 million, compared to $19.0 million for the same period in 2008. Third quarter net revenue was reduced by a change in estimate of expected third-party payor reimbursements based upon their cash collection behavior over the past fifteen months. The Company's loss from continuing operations before income taxes for the third quarter of 2009 was $3.2 million compared with an operating loss of $2.2 million for the same period of 2008. The company's net loss for the third quarter 2009 was $3.2 million, or $0.04 per share applicable to common stockholders. In the third quarter of 2008, the Company reported a net loss of $2.2 million, or $0.03 per share applicable to common stockholders. Adjusted EBITDA for the 2009 third quarter was a negative $1.6 million, compared to adjusted EBITDA of $1.4 million in the third quarter of 2008. The company reported loss from operations of $3.1 million or $0.04 per share against income from operations of $185,000 or $0.03 per share for the same period a year ago. Net revenue for this year's first nine months was $68.3 million, a 32% increase from $51.8 million over the prior year period. For the nine months ended September 30, 2009, loss from continuing operations before income taxes was $4.9 million compared to a loss from continuing operations before income taxes of $7.4 million for the nine months ended September 30, 2008. For the nine months ended September 30, 2009 and 2008, the net loss was $3.4 million and $7.4 million, respectively. Net loss per share applicable to common stockholders for the nine months ended September 30, 2009 and 2008 was $0.10 and $0.10, respectively. For the 2009 nine-month period, adjusted EBITDA was $3.1 million, compared to adjusted EBITDA of $2.6 million in the prior year period, an increase of 19%. The company reported loss from operations of $806,000 or $0.11 per share against loss from operations of $1.7 million or $0.10 per share for the same period a year ago. The company revised revenues outlook for the full year of 2009. The company is now revising their revenue guidance for 2009 to $90 million to $94 million from the previous range of $96 million to $101 million. Even at the low end of the range, this will represent a year-over-year growth rate of greater than 22% from 2008 revenues of $73.7 million.
Clarient, Inc., Q3 2009 Earnings Call, Nov-03 2009
Clarient, Inc. expected to Report Fiscal Year 2009 Results on March 11, 2010. This event was calculated by Capital IQ (Created on October 29, 2009).
CLRT Competitors
| Company | Last | Change |
| CytoCore Inc | $0.16 USD | -0.02 |
| Exiqon A/S | kr10.00 DKK | 0.00 |
| Genomic Health Inc | $19.29 USD | +0.25 |
| Genoptix Inc | $36.46 USD | +0.58 |
| Laboratory Corporation of America Hldgs | $73.66 USD | +0.29 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | CLRT | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 2.1x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.6x |
|
|
CLRT |
||
CLRT transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
